Version history

{
  "session_id": "sess-hyp-822bfd0cb891",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "llm",
  "action": "support",
  "content": "\n\n# Expert Assessment: ALOX15-Driven Ferroptosis in AD Oligodendrocytes\n\n## Executive Summary\n\nThis hypothesis presents a mechanistically plausible pathway connecting ALOX15 enzymatic activity to oligodendrocyte death via ferroptosis in Alzheimer's Disease. The target has favorable druggability characteristics and a history of drug discovery efforts, though significant translational challenges exist, particularly regarding human relevance in AD and safety liabilities from eicosanoid pathway modulation.\n\n**Confidence Score: 0.62** (revised downward from 0.82 given translational context)\n\n---\n\n## 1. Druggability Assessment\n\n### Target Characteristics\n| Property | Assessment | Notes |\n|----------|------------|-------|\n| Enzyme class | Non-heme iron dioxygenase | Well-characterized structure; ~75 kDa cytosolic protein |\n| Active site | Druggable | Iron-centered active site; confirmed crystallographic data |\n| Binding pockets | Defined | Multiple structural features amenable to small molecule engagement |\n| Previous attempts | Extensive | Investigated for asthma, MS, cardiovascular disease, oncology |\n\n**Verdict**: ALOX15 is a druggable target with established medicinal chemistry precedent. The active site iron creates both opportunities (high-affinity chelation-based inhibitors) and challenges (specificity across lipoxygenase family).\n\n---\n\n## 2. Tool Compounds Assessment\n\n### Existing Research Tools\n\n| Compound | Specificity | Limitation |\n|----------|-------------|------------|\n| **PD146176 (BL-0007)** | Selective for ALOX15 | Developed for EAE/MS; limited",
  "tokens_used": "395",
  "persona_id": "persona-domain_expert"
}